藥物有效，但停藥之後，體重去哪了？
GLP-1 Works — But What Happens After You Stop?
如果你正在使用 GLP-1 藥物（Ozempic、Wegovy）或猛健樂（tirzepatide），你可能已經感受到它帶來的改變——食慾下降、體重開始減輕。但幾乎所有患者最終都會問同一個問題：「這個體重能維持嗎？停了之後呢？」
If you're using a GLP-1 medication (Ozempic, Wegovy) or Mounjaro (tirzepatide), you've likely felt the effects — reduced appetite, steady weight loss. But nearly every patient eventually asks: "Can I keep this weight off? What happens when I stop?"
兩項最大規模的臨床延伸試驗，給出了殘酷的數字：
Two landmark clinical extension trials gave us an honest answer:
1 年內平均復胖比例
(STEP-1 延伸試驗)
within 1 year of stopping semaglutide
(STEP-1 Extension)
52 週內減重效果消失比例
(SURMOUNT-4)
within 52 weeks of stopping tirzepatide
(SURMOUNT-4)
所需時間（停藥後）
(系統性回顧, Lancet 2026)
to baseline weight after stopping
(Systematic Review, Lancet 2026)
這不是患者的失敗。GLP-1 藥物的作用原理是調整荷爾蒙訊號（GLP-1 受體、GIP 受體）來抑制食慾——但一旦停藥，這些訊號隨即消退，身體會重新回到它原本熟悉的代謝狀態。停藥後的復胖，同時也伴隨血壓、血脂、血糖等心血管危險因子的回升。
This isn't patient failure. GLP-1 medications work by modulating hormone signals to suppress appetite — but once stopped, those signals fade, and the body reverts to its previous metabolic baseline. Weight regain after discontinuation is also accompanied by worsening cardiovascular risk factors including blood pressure, lipids, and blood glucose.
GLP-1 藥物改變的是荷爾蒙訊號，代謝手術改變的是消化道結構。手術的效果不依賴每週施打，也不受停藥影響。
GLP-1 medications change hormone signals; metabolic surgery changes gastrointestinal anatomy. Surgery's effects don't require weekly injections and aren't lost on discontinuation.
你的藥，效果達標了嗎？
Is Your Medication Working Well Enough?
並非每個人對 GLP-1 的反應都一樣。即使達到建議治療劑量，研究顯示仍有一定比例的患者減重效果有限：
Not everyone responds equally to GLP-1 therapy. Even at therapeutic doses, a meaningful proportion of patients achieve limited weight loss:
| 藥物 | Medication | 無效率（減重 < 5% 體重） | Non-Response Rate (<5% weight loss) |
|---|---|---|---|
| Liraglutide（每日針） | Liraglutide (daily injection) | 27.1% | |
| Semaglutide（每週針 / Ozempic、Wegovy） | Semaglutide (weekly / Ozempic, Wegovy) | 19.1% | |
| Tirzepatide（每週針 / 猛健樂） | Tirzepatide (weekly / Mounjaro) | 2.7% |
依據 ASMBS/IFSO 2022 年更新指引所確立的框架，並結合 2023–2024 年肥胖醫學臨床共識：在治療劑量下使用 GLP-1，若達上述條件，建議轉介代謝手術評估。
Based on the framework established in the 2022 ASMBS/IFSO updated guidelines and 2023–2024 obesity medicine clinical consensus: when these criteria are met at therapeutic GLP-1 dose, referral for metabolic surgery evaluation is recommended.
以下這些信號，是值得和醫師認真討論的時機：
These signs are worth discussing seriously with your doctor:
- 打了 GLP-1 超過 6 個月，體重下降不足體重的 10% Used GLP-1 for 6+ months with less than 10% total weight loss
- 體重已明顯停滯，即使增加劑量也沒有突破 Weight has plateaued despite dose escalation
- 停藥或減量後，體重迅速回升 Significant weight rebound after stopping or reducing dose
- 長期無法負擔每月藥費，但體重管理仍是必要需求 Unable to sustain long-term medication costs, but weight management remains critical
- 有第 2 型糖尿病，希望追求疾病「緩解」而非長期服藥控制 Have type 2 diabetes and seeking disease remission rather than lifelong medication
- BMI ≥ 35 且合併高血壓、睡眠呼吸中止或血脂異常 BMI ≥35 with comorbidities (hypertension, sleep apnea, dyslipidemia)
若你的起始 BMI 原本就偏高（≥ 35 或 ≥ 40），使用 GLP-1 或猛健樂後體重雖有所下降，但往往在距離理想體重還有相當距離時就進入停滯期。這不是藥物失敗，而是藥物的天花板。
If your starting BMI was already elevated (≥35 or ≥40), GLP-1 or Mounjaro may reduce your weight meaningfully — but often plateaus well before a healthy target weight is reached. This isn't failure; it's the ceiling of what medication can do.
接續代謝手術可以做到三件藥物做不到的事：延伸減重幅度突破高原、改變消化道結構使效果不依賴用藥、大幅降低停藥後復胖的風險。
Subsequent metabolic surgery achieves three things medication cannot: extends weight loss beyond the plateau, creates structural change independent of ongoing medication, and substantially reduces rebound risk after stopping GLP-1.
→ 延伸閱讀：BMI 偏高，為什麼手術的 CP 值遠優於長期用藥？（美國最新實證）
→ See also: High BMI: Why Surgery Offers Far Better Value Than Long-Term Medication (US evidence)
手術 vs. 藥物：最新真實世界數據怎麼說？
Surgery vs. Medication: What the Latest Real-World Data Shows
2025 年發表於 JAMA Surgery 的大型研究，直接比較了 30,458 名真實患者——結果清楚：
A major 2025 study published in JAMA Surgery compared 30,458 real-world patients head to head — the results are striking:
2 年平均減重幅度
（約 31 公斤）
avg. weight loss at 2 years
(~69 lbs)
2 年平均減重幅度
（約 11 公斤）
avg. weight loss at 2 years
(~25 lbs)
長期維持 10 年以上
than medication
durable for 10+ years
📌 為什麼是 10.3%，藥廠說的不是 15–22% 嗎？
臨床試驗（如 STEP-1、SURMOUNT-1）的 15–22% 減重效果，是在高度篩選、密集追蹤的受試者中所得——依從性接近 100%、劑量精準調控。
真實世界截然不同：約 53% 的患者在 1 年內停藥，2 年累積停藥率達 72%，原因包括副作用、費用負擔、保險中斷等。一旦將所有真實患者（包含提早停藥者）納入分析，整體族群的平均減重效果便下降至約 10.3%——仍比臨床試驗數據低 30–50%。這才是現實中大多數患者面對的數字。
📌 Why 10.3%? Didn't the drug companies report 15–22%?
The 15–22% weight loss in clinical trials (STEP-1, SURMOUNT-1) comes from highly selected, intensively monitored participants with near-perfect adherence and optimised dosing.
Real-world reality differs: ~53% of patients stop GLP-1 within 1 year; by 2 years, ~72% have discontinued — due to side effects, cost, and insurance gaps. When all real-world patients (including early discontinuers) are included, the population-level average drops to ~10.3% — still 30–50% below clinical trial benchmarks. This is what the evidence shows for most patients in practice.
| GLP-1 藥物 | GLP-1 Medication | 代謝手術 | Metabolic Surgery | ||
|---|---|---|---|---|---|
| 2 年減重幅度 | 2-Year Weight Loss | 10.3% | 28.3% | ||
| 停止「治療」後效果 | Effect After Stopping Treatment | 停藥後體重回升 | Weight returns after stopping | 永久改變消化道結構 | Permanent anatomical change |
| 第 2 型糖尿病緩解率 | T2DM Remission Rate | ~10–15% | 50–80% | ||
| 長期費用（2 年） | Long-term Cost (2 yrs) | 持續支出 | Ongoing monthly cost | 平均節省 ~$11,689 美元 | Saves ~$11,689 vs. medication |
| 可逆性 | Reversibility | 可停藥 | Can discontinue | 多數術式不可逆 | Most procedures permanent |
Brigham and Women's Hospital 的研究（182 對 182 人）顯示，術前長期使用 semaglutide 的患者，其術後 2 個月及 6 個月的減重成效，與直接手術組沒有顯著差異。對於 BMI 較高的患者，「手術優先」策略反而更能帶來整體改善。
A study from Brigham and Women's Hospital (182 vs. 182 patients) found that pre-operative semaglutide use produced no significant difference in weight loss outcomes at 2 or 6 months post-surgery. A "surgery-first" approach may be more effective for high-BMI patients with multiple comorbidities.
GLP-1 使用者，哪一種手術最適合你？
Which Surgery Fits GLP-1 Users Best?
不同的代謝手術有不同的適應症。以下是三種常見術式的特點，及其與 GLP-1 使用情境的配對：
Different metabolic procedures suit different patient profiles. Here's how the three most common options compare for GLP-1 users:
多數患者術後對 GLP-1 的需求大幅降低，甚至不再需要。手術本身會改變腸道荷爾蒙的分泌模式，達到類似 GLP-1 藥物的部分效果——但更持久、更全面。少數患者在術後體重停滯時，可以 GLP-1 作為輔助，兩者並不衝突。
Most patients significantly reduce or eliminate their need for GLP-1 after surgery. The procedure itself reshapes gut hormone secretion patterns — achieving some of GLP-1's effects but more durably and comprehensively. A minority of patients may use GLP-1 adjunctively post-operatively; surgery and medication are not mutually exclusive.
GLP-1 使用者最常問的 5 個問題
5 Questions GLP-1 Users Most Commonly Ask
術前還需要先打 GLP-1 再手術嗎？
Do I need to keep using GLP-1 before surgery?
不需要。大型研究顯示，術前長期使用 GLP-1 並不會讓術後的長期減重效果更好。反而，對於 BMI 高、共病多的患者，手術優先策略能帶來更全面的改善。唯一例外是麻醉安全考量——手術前約 1–2 週，醫師通常會建議暫停 GLP-1，以降低術中胃排空延遲的風險。
No. Large-scale studies show that pre-operative GLP-1 use does not improve long-term post-surgical weight loss. For high-BMI patients with multiple comorbidities, a surgery-first strategy often produces better overall outcomes. The only exception is anaesthetic safety: most surgeons recommend stopping GLP-1 1–2 weeks before surgery to reduce the risk of delayed gastric emptying during anaesthesia.
健保有給付減重手術嗎？需要符合什麼條件？
Does Taiwan's NHI cover bariatric surgery? What are the criteria?
台灣健保目前針對以下兩類族群給付代謝減重手術：
- BMI ≥ 37.5，無論是否合併其他疾病
- BMI ≥ 32.5，且合併有第二型糖尿病（HbA1c 經治療仍 ≥ 7.5%）、高血壓、或睡眠呼吸中止症等高危險代謝疾病
申請尚需符合術前評估與病歷紀錄等審查條件。詳細說明請參考本站常見問題頁，或預約門診由醫師協助評估資格。
Taiwan's NHI currently covers metabolic bariatric surgery for patients who meet one of the following:
- BMI ≥ 37.5 — regardless of other conditions
- BMI ≥ 32.5 with a high-risk metabolic comorbidity: Type 2 diabetes (HbA1c ≥ 7.5% despite treatment), hypertension, or obstructive sleep apnea
Additional pre-operative evaluation and documentation requirements apply. See our FAQ page for full details, or book a consultation to have your eligibility assessed.
停藥後體重已經回升，還能手術嗎？
I regained weight after stopping GLP-1 — can I still have surgery?
可以，而且停藥後復胖本身就是手術評估的重要指標之一。研究顯示，代謝手術對於曾使用 GLP-1 後復胖的患者，仍能帶來顯著且持久的減重效果，且效果優於重新嘗試藥物治療。
Yes, and post-GLP-1 rebound weight gain is itself an important indicator for surgical evaluation. Research shows that metabolic surgery delivers significant, durable weight loss even for patients who previously regained weight after stopping GLP-1 medication — and outcomes are superior to restarting medication.
我 BMI 只有 32，也有手術評估的機會嗎？
My BMI is only 32 — can I still be evaluated for surgery?
根據 2022 年 ASMBS/IFSO 最新指引，BMI 在 30–34.9 且合併代謝疾病（糖尿病、高血壓、血脂異常等）的患者，已可考慮代謝手術評估。手術的適應症不再僅限於 BMI ≥ 40。建議與專科醫師討論個人的整體代謝狀況。
According to the 2022 ASMBS/IFSO updated guidelines, patients with BMI 30–34.9 and metabolic disease (diabetes, hypertension, dyslipidaemia, etc.) are now eligible for bariatric surgery consideration. Eligibility is no longer limited to BMI ≥40. A specialist consultation to review your overall metabolic profile is the right starting point.
GLP-1 和手術可以同時並行嗎？
Can GLP-1 and surgery be used together?
可以。GLP-1 與代謝手術不是對立的。部分患者在手術後體重出現高原期，會以較低劑量的 GLP-1 作為輔助工具。也有患者在手術後代謝改善顯著，完全不再需要藥物。兩者的搭配方式，應依術後評估結果與個人狀況由醫師決定。
Yes. GLP-1 and metabolic surgery are not mutually exclusive. Some patients use low-dose GLP-1 adjunctively when weight plateaus post-operatively. Others achieve such significant metabolic improvement after surgery that they need no medication at all. The appropriate combination depends on individual post-operative outcomes and should be determined with your surgeon.
考慮下一步？預約門診評估
Ready to Explore the Next Step?
如果你正在使用 GLP-1 或猛健樂，或停藥後面臨復胖，林育弘醫師的門診提供完整的代謝手術評估，協助你找到最適合的長期解決方案。
If you're on GLP-1 or Mounjaro — or facing rebound after stopping — Dr. Yu-Hung Lin's clinic offers a comprehensive metabolic surgery evaluation to help you find the right long-term solution.
📚 參考文獻
📚 References
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022. PMC9542252
- Aronne LJ et al. SURMOUNT-4: Tirzepatide discontinuation results in weight regain. J Clin Endocrinol Metab. 2024–2025. ACC.org
- Trajectory of weight regain after cessation of GLP-1 receptor agonists: systematic review and nonlinear meta-regression. eClinicalMedicine / The Lancet. 2026. The Lancet
- Berg J et al. Discontinuing GLP-1 receptor agonists and body habitus: systematic review and meta-analysis. Obesity Reviews. 2025. Wiley
- Head-to-head study: Bariatric Surgery Superior to GLP-1 Drugs for Weight Loss. ASMBS 2025 Annual Scientific Meeting. ASMBS
- Bariatric Surgery vs. GLP-1 RAs — cohort study (n = 30,458). JAMA Surgery. 2025. ASMBS Summary
- Neoadjuvant Semaglutide before Bariatric Surgery: no long-term weight loss benefit. Mass General Brigham / JAMA Surgery. 2025. Renal & Urology News
- Eisenberg D et al. 2022 ASMBS/IFSO Indications for Metabolic and Bariatric Surgery. Surgery for Obesity and Related Diseases. 2022. PubMed 36336720